PDCD1 and non-small cell lung carcinoma: In addition to its effect on the resistance to traditional chemotherapy drugs, miR‐381 also affects the resistance of NSCLC to immunotherapy, such as anti‐programmed cell death protein 1 (PD‐1)‐based therapy.